肺动脉高血压中的EP4/ANXA2轴:治疗影响
Hu Xu1,2, Lan Ye3, Chunxiu Du1
1Health Science Center, East China Normal University, No. 500, Dongchuan Road, Shanghai 200241, China.
European heart journal
|September 25, 2025
概括
向EP4和附件A2 (ANXA2) 显示出治疗肺动脉高血压 (PAH) 的前景. 在动物模型中,阻断EP4或ANXA2改善了PAH和肺动脉重塑.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 涉及肺动脉光滑肌细胞的增殖和重塑.
- 前列腺素E2及其受体EP4是血管恒温的关键.
- EP4在PAH病原发生中的作用及其治疗潜力需要研究.
研究的目的:
- 确定EP4在PAH病原发生中的作用.
- 评估EP4作为PAH的治疗点.
主要方法:
- 采用单克罗他林诱导的老鼠和缺氧/Su5416诱导的小鼠PAH模型.
- 使用药理学EP4抗剂/激动剂和遗传策略 (VSMC特定的EP4淘汰/转基因小鼠).
- 使用细胞和分子生物学方法研究机制.
主要成果:
- EP4阻塞或VSMC删除EP4显著改善了PAH和肺动脉重塑.
- EP4激活或VSMC过度表达加剧了PAH.
- EP4激活通过cAMP/PKA增强附件A2 (ANXA2) 的翻译和酸化,促进PASMC的增殖和迁移.
- 在动物中防止PAH的ANXA2抑制或删除.
结论:
- 确定了涉及EP4和ANXA2在PAH发展和进展中的关键途径.
- 针对EP4及其下游效应器ANXA2,为PAH提供了有前途的治疗策略.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
442
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
442
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
462
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
462
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
560
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
560
Pulmonary Hypertension: Classification and Pathogenesis
576
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
576
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
589
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
589


